Market Place
Sourcing Support
Neupath Health to be Featured On Radius Research Webinar
21 Oct 2024 //
BUSINESSWIRE
US FDA grants approval for Radius’ Tymlos for osteoporosis in men
22 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
11 Oct 2022 //
PHARMAINTELLIGENCE
Gurnet Point & Patient Square Complete Their Acquisition of Radius Health
15 Aug 2022 //
GLOBENEWSWIRE
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
11 Aug 2022 //
BUSINESSWIRE
Radius Announces First Patient Randomized in RAD011 Pivotal Trial for PWS
07 Jul 2022 //
GLOBENEWSWIRE
Radius Health Publishes Investor Presentation Outlining Company`s Progress
07 Jul 2022 //
GLOBENEWSWIRE
2 investment firms buy Radius, bone drug Tymlos for $890M
24 Jun 2022 //
FIERCEPHARMA
Menarini Group and Radius Health Submit NDA to the U.S. FDA for Elacestrant
22 Jun 2022 //
PRNEWSWIRE
Radius Health Expands Non-US Market Footprint for TYMLOS
08 Jun 2022 //
GLOBENEWSWIRE
Activist investors attempt to change the course at Radius Health
07 Jun 2022 //
ENDPTS
Radius Files Definitive Proxy and Mails Letter to Stockholders
06 Jun 2022 //
GLOBENEWSWIRE
Menarini, Radius Health present analysis from elacestrant PIII trial at 2022
06 Jun 2022 //
PRNEWSWIRE
Radius Health Update on Abaloparatide Transdermal System
01 Jun 2022 //
GLOBENEWSWIRE
Radius Adds Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
20 May 2022 //
GLOBENEWSWIRE
Radius Health, Inc. First Quarter 2022 Results
05 May 2022 //
GLOBENEWSWIRE
Roche hit with another key R&D setback as oral SERD flops in breast cancer
26 Apr 2022 //
FIERCEBIOTECH
Radius Provides Agenda for Today`s R&D Webcast
05 Apr 2022 //
GLOBENEWSWIRE
Radius Health says Leadership Appointments
16 Mar 2022 //
GLOBENEWSWIRE
Radius Health Provides Business Update on Bone Health
08 Mar 2022 //
GLOBENEWSWIRE
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
07 Mar 2022 //
GLOBENEWSWIRE
Radius to Host Neuroscience R&D Webcast April 5, 2022
03 Mar 2022 //
GLOBENEWSWIRE
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
24 Feb 2022 //
PRESS RELEASE
Radius Announces Update on TYMLOS® (abaloparatide) Label
23 Dec 2021 //
GLOBENEWSWIRE
Radius Announces Update on TYMLOS® (abaloparatide) Label
23 Dec 2021 //
GLOBENEWSWIRE
Radius falters after PhIII osteoporosis drug fail & breast cancer disappointment
10 Dec 2021 //
ENDPTS
Radius takes a tumble
09 Dec 2021 //
EVALUATE
Menarini, chased by 3 Big Pharmas, records breast cancer win
22 Oct 2021 //
FIERCEBIOTECH
Radius rockets higher as Kelly Martin boasts of a big PhIII success
21 Oct 2021 //
YAHOOFINANCE
Radius Announces Positive Phase 3 Topline Results for TYMLOS®
18 Oct 2021 //
GLOBENEWSWIRE
Radius Health gains 7% as owner buys more shares
27 Sep 2021 //
SEEKINGALPHA
TYMLOS Label and Business Update
22 Sep 2021 //
GLOBENEWSWIRE
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
22 Jul 2021 //
GLOBENEWSWIRE
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
22 Jul 2021 //
GLOBENEWSWIRE
Radius Health Provides Update on Abaloparatide
24 Mar 2021 //
GLOBENEWSWIRE
Radius Health, Inc. Announces Acquisition of Orphan Disease Program
05 Jan 2021 //
GLOBENEWSWIRE
Radius Health Divests RAD 140 Program to Ellipses Pharma
01 Oct 2020 //
GLOBENEWSWIRE
Radius Health & Menarini-Gruppe liefern Elacestrant Update
27 Sep 2020 //
PRNEWSWIRE
Radius Health & Menarini Group Provide Elacestrant Update
25 Sep 2020 //
PRNEWSWIRE
Radius Health & Menarini Group Provide Elacestrant Update
24 Sep 2020 //
PRNEWSWIRE
Radius Health: Enrollment Completed for Phase 3 wearABLe trial
08 Sep 2020 //
PRESS RELEASE
